Novartis Analyst Ratings
Novartis Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 05/09/2022 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/06/2021 | — | Exane BNP Paribas | Downgrades | Outperform → Neutral | |
| 12/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 09/20/2021 | — | Deutsche Bank | Downgrades | Hold → Sell | |
| 03/10/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/01/2021 | 3.82% | Cowen & Co. | $110 → $105 | Downgrades | Outperform → Market Perform |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 09/01/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 02/25/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/25/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 04/10/2019 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 12/11/2018 | 3.82% | Jefferies | → $105 | Assumes | → Buy |
| 11/26/2018 | -1.13% | Cowen & Co. | → $100 | Upgrades | Market Perform → Outperform |
| 11/19/2018 | — | Goldman Sachs | Upgrades | Neutral → Conviction Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/25/2023 | - | 摩根士丹利 | 升级 | 重量不足的→等重 | |
| 05/09/2022 | - | 沃尔夫研究 | 评级下调 | 超越→同行的表现 | |
| 12/06/2021 | - | 法国巴黎银行 | 评级下调 | 跑赢→中性 | |
| 12/03/2021 | - | 布莱恩·加尼耶 | 评级下调 | 购买→中性 | |
| 09/20/2021 | - | 德意志银行 | 评级下调 | 持有→Sell | |
| 03/10/2021 | - | Argus研究 | 评级下调 | 购买→Hold | |
| 02/01/2021 | 3.82% | 考恩公司 | $110→$105 | 评级下调 | 跑赢→市场表现 |
| 2021/01/15 | - | 德意志银行 | 开始承保 | →购买 | |
| 09/01/2020 | - | 摩根士丹利 | 升级 | 等重→超重 | |
| 02/25/2020 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 2019年04月25日 | - | 古根海姆 | 升级 | 中性→购买 | |
| 2019年04月10日 | - | 摩根士丹利 | 评级下调 | 等重→减码 | |
| 2018年12月11日 | 3.82% | 杰富瑞 | →$105 | 假设 | →购买 |
| 2018年11月26日 | -1.13% | 考恩公司 | →$100 | 升级 | 市场表现优于→ |
| 2018年11月19日 | - | 高盛 | 升级 | 中性→定罪买入 |
What is the target price for Novartis (NVS)?
诺华(Novartis)的目标价是多少？
The latest price target for Novartis (NYSE: NVS) was reported by Morgan Stanley on September 25, 2023. The analyst firm set a price target for $0.00 expecting NVS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
诺华公司(纽约证券交易所代码：NVS)的最新目标价是由摩根士丹利于2023年9月25日报道的。这家分析公司将NVS的目标价设定为0.00美元，预计NVS将在12个月内下降(跌幅可能为-100.00%)。1家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Novartis (NVS)?
分析师对诺华(Novartis)的最新评级是多少？
The latest analyst rating for Novartis (NYSE: NVS) was provided by Morgan Stanley, and Novartis upgraded their equal-weight rating.
分析师对诺华公司(纽约证券交易所股票代码：NVS)的最新评级由摩根士丹利提供，诺华公司上调了其同等权重的评级。
When is the next analyst rating going to be posted or updated for Novartis (NVS)?
诺华公司(Novartis)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查看公开的财务报表，与诺华的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。诺华的上一次评级是在2023年9月25日提交的，所以你应该预计下一次评级将在2024年9月25日左右的某个时候公布。
Is the Analyst Rating Novartis (NVS) correct?
分析师对诺华(Novartis)的评级正确吗？
While ratings are subjective and will change, the latest Novartis (NVS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novartis (NVS) is trading at is $101.14, which is out of the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但诺华(Novartis)最新的评级被上调，目标价从0.00美元到0.00美元。诺华公司目前的股价为101.14美元，超出了分析师的预测范围。